Lv6
2280 积分 2021-11-01 加入
What are the right endpoints to assess the effectiveness of new treatments for IgAN?
13天前
已完结
Research Progress on Membranous Nephropathy-Related Antigens and Immune-Targeted Therapy
13天前
已完结
Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions
21天前
已完结
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
23天前
已完结
Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review
23天前
已关闭
Mucin O-glycosylation and B-cell homing: a new bridge for the gut-kidney axis in IgA nephropathy?
26天前
已完结
Predictive Value of the Oxford Classification for the Effect of Glucocorticoid Therapy in IgA Nephropathy
28天前
已完结
What are the right endpoints to assess the effectiveness of new treatments for IgAN?
1个月前
已完结
Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR
1个月前
已完结
A practical guide to the appropriate analysis of eGFR data over time: A simulation study
1个月前
已完结
皖公网安备34019202002308